Details
Stereochemistry | ACHIRAL |
Molecular Formula | C20H25NOS.ClH |
Molecular Weight | 363.945 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.CCN(CC)CCSC(=O)C(C1=CC=CC=C1)C2=CC=CC=C2
InChI
InChIKey=MZWKCFGWAWRHDY-UHFFFAOYSA-N
InChI=1S/C20H25NOS.ClH/c1-3-21(4-2)15-16-23-20(22)19(17-11-7-5-8-12-17)18-13-9-6-10-14-18;/h5-14,19H,3-4,15-16H2,1-2H3;1H
Thiphenamil, an antispasmodic drug with a local anesthetic activity, inhibits contraction. The clinical trials have shown that thiphenamil could suppress upper urinary tract contractility, and was suggested to use the drug for renal colic and stone management. In addition, this drug was studied for the treatment of detrusor incontinence in patients with detrusor instability. The results showed, that the drug caused a significant decrease in problems due to loss of urine when the patient was taking the drug compared to the placebo.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: smooth muscle Sources: https://www.ncbi.nlm.nih.gov/pubmed/1528051 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
Doses
Dose | Population | Adverse events |
---|---|---|
400 mg 4 times / day steady, oral Recommended Dose: 400 mg, 4 times / day Route: oral Route: steady Dose: 400 mg, 4 times / day Sources: |
unhealthy, 44 years n = 16 Health Status: unhealthy Condition: detrusor incontinence Age Group: 44 years Sex: M Population Size: 16 Sources: |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/1598732
The pharmacologic effect of thiphenamil HCl on the upper urinary tract as a relaxant of renal pelvic contractions was studied. A total of 17 subjects with no known upper urinary tract abnormalities were scanned. The subject was then given a single dose of 400 mg thiphenamil HCl and visualization of contractility continued for approximately 60-90 min.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/2231955
The relaxation mechanism of the antispasmodics, papaverine and thiphenamil on isolated human corpus cavernosum (CC) was investigated. CC tissues were obtained from 12 impotent men undergoing surgery for insertion of penile prostheses. CC preparations were mounted in a tissue bath and the isometric tension was recorded. Papaverine and thiphenamil consistently inhibited high-potassium ([K])-induced contractions in a dose-dependent manner. The pD'2 values were 4.77 +/- 0.20 for papaverine and 4.58 +/- 0.13 for thiphenamil. The results suggest that papaverine and thiphenamil relax CC tissue by the inhibition of extracellular Ca2+ influx (mainly voltage-dependent Ca2+ influx) and by the inhibition of release and/or storage of intracellular stored Ca2+.
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C29704
Created by
admin on Fri Dec 15 15:10:13 GMT 2023 , Edited by admin on Fri Dec 15 15:10:13 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
C009488
Created by
admin on Fri Dec 15 15:10:13 GMT 2023 , Edited by admin on Fri Dec 15 15:10:13 GMT 2023
|
PRIMARY | |||
|
m10794
Created by
admin on Fri Dec 15 15:10:13 GMT 2023 , Edited by admin on Fri Dec 15 15:10:13 GMT 2023
|
PRIMARY | Merck Index | ||
|
548-68-5
Created by
admin on Fri Dec 15 15:10:13 GMT 2023 , Edited by admin on Fri Dec 15 15:10:13 GMT 2023
|
PRIMARY | |||
|
208-955-7
Created by
admin on Fri Dec 15 15:10:13 GMT 2023 , Edited by admin on Fri Dec 15 15:10:13 GMT 2023
|
PRIMARY | |||
|
CHEMBL1450486
Created by
admin on Fri Dec 15 15:10:13 GMT 2023 , Edited by admin on Fri Dec 15 15:10:13 GMT 2023
|
PRIMARY | |||
|
DTXSID30203284
Created by
admin on Fri Dec 15 15:10:13 GMT 2023 , Edited by admin on Fri Dec 15 15:10:13 GMT 2023
|
PRIMARY | |||
|
4OQ4SP44R2
Created by
admin on Fri Dec 15 15:10:13 GMT 2023 , Edited by admin on Fri Dec 15 15:10:13 GMT 2023
|
PRIMARY | |||
|
11060
Created by
admin on Fri Dec 15 15:10:13 GMT 2023 , Edited by admin on Fri Dec 15 15:10:13 GMT 2023
|
PRIMARY | |||
|
C87646
Created by
admin on Fri Dec 15 15:10:13 GMT 2023 , Edited by admin on Fri Dec 15 15:10:13 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD